1. Bromodeoxyuridine incorporation into DNA of human leukemia cells is not concentration dependent
- Author
-
Gregory Bw, Bayard L. Powell, E. Susan Lyerly, Timothy M. Morgan, Robert L. Capizzi, and Timothy E. Kute
- Subjects
Biophysics ,Biology ,Pathology and Forensic Medicine ,Flow cytometry ,chemistry.chemical_compound ,Endocrinology ,medicine ,Humans ,Propidium iodide ,Acute leukemia ,medicine.diagnostic_test ,Antibodies, Monoclonal ,Cell Biology ,Hematology ,DNA, Neoplasm ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Flow Cytometry ,Molecular biology ,Immunohistochemistry ,Leukemia ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Biochemistry ,chemistry ,Bromodeoxyuridine ,Monoclonal ,Bone marrow ,Nucleoside - Abstract
Leukemia blasts isolated from bone marrow aspirates of 44 adults with acute leukemia were incubated for 1 h with 0.008-32 microM bromodeoxyuridine (Brd-Urd). After dual labeling with monoclonal anti-BrdUrd antibodies and propidium iodide, the cells were analyzed by flow cytometry. Percent labeled cells and intensity of labeling were similar over concentrations of BrdUrd ranging from 0.8-32 microM--a 40-fold range. Therefore, despite potential interpatient variability in nucleoside pharmacokinetics, commonly used doses of BrdUrd which are intended to achieve steady-state plasma concentrations in the 8.0 microM range can be expected to provide a reliable estimate of the S-phase fraction.
- Published
- 1990